Early TMTV Changes on FDG-PET/CT Predict Long-Term Outcomes in Patients Treated With Pembrolizumab for Advanced Melanoma
Source: Cancer Therapy Advisor, May 2021
In patients with advanced melanoma, total metabolic tumor volume (TMTV) changes on 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) 2 to 4 months after the start of therapy with pembrolizumab may predict long-term response and survival, according to a study in published in Current Oncology.
